During the follow-up of up to 132 months after NAT-PML, inflammatory MS disease activity was a rarity, but a major proportion of patients had a progressive EDSS increase indicative of ongoing neurodegenerative disease processes. This evidence concerns the gene PML and neurodegenerative disease.